RA Capital leads $125M for Janux in VC's latest crossover bid
Four months ago, only a short list of people had ever heard of Janux Therapeutics. Today, they have a partnership with Merck, $212 million in VC capital and, it seems, plans for an IPO.
Janux announced Tuesday a $125 million crossover round led by RA Capital, the Boston VC behind a spate of recent pre-IPO financings. Janux declined an interview request, a common move for biotechs preparing to go public in the near future.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters